Latigo Biotherapeutics Inc. filed for an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.

The Blue Owl Capital Inc. -backed clinical-stage developer of non-opioid pain medicines has one drug candidate in late-stage trials that has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, according to its filing Friday with the US Securities and Exchange Commission.

拉蒂戈生物制药公司（Latigo Biotherapeutics Inc.）已提交首次公开募股申请，成为越来越多考虑在本季度上市的生物技术企业中的一员。

根据周五提交给美国证券交易委员会的文件，由蓝猫头鹰资本公司（Blue Owl Capital Inc.）支持的非阿片类止痛药临床阶段研发企业，目前有一种候选药物处于后期试验阶段。该药物的镇痛效果比同类阿片类药物维柯丁（Vicodin）高出约 50%。